Clinical trials: Involuntary Movements
Primary Lateral Sclerosis
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Objective: The objectives of this protocol are: to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, to characterize the natural history of…
- Trial name
- NCT00015444
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Tardive Dyskinesia, Intellectual Disability
Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
The goal of this open-label clinical trial is to test the safety and efficacy of valbenazine treatment in patients with Intellectual/Developmental Disability (IDD) who have a diagnosis of Tardive dyskinesia (TD).
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06107829)
- Testing
- Valbenazine Oral Capsule
- Where
- United States
- Sponsor
- Stephen Ruedrich
Movement Disorders
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
BTX has been used since the 1980s in support of the research mission of NINDS. Initial studies were focused on expanding the applicability of BTX treatment to movement disorders and exploring new indications.
- Trial name
- NCT00001208
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Movement, Involuntary
NIBP (Non-invasive Blood Pressure) Algorithm Enhancements (Characterize the Robustness of Motion Artifact Suppression)
The study intervention consists of a non-invasive blood pressure (NIBP) measurement device and cuff (FDA-cleared Philips IntelliVue X3 Rev.
- Trial name
- NCT05185037
- Testing
- Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Parkinson's Disease
Effect of Deep Brain Stimulation on Gastrointestinal (GI) Motility
Parkinson's disease is characterized by extra-pyramidal symptoms as well as digestive involvement with gastrointestinal motility (GI) impairment.
- Trial name
- SCP-Comodig (NCT01081457)
- Testing
- Deep brain stimulation
- Where
- France
- Volunteers
- 16 people
- Sponsor
- University Hospital, Rouen
GNAO1, Dystonia
Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders
The goal of this clinical trial is to investigate feasibility and safety of an oral therapy with zinc in patients affected by Guanine nucleotide-binding protein G(o) subunit alpha (GNAO1) associated disorders.
- Conditions
- GNAO1, Dystonia, Epilepsy, Development Delay
- Trial name
- ZINCGNAO1 (NCT06412653)
- Testing
- Zinc Acetate Dihydrate
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Children's University Hospital Cologne, Germany
Movement, Involuntary
Assessment of the Effects of Mental Practice on Tongue Strength in Brain-damaged Patients
The main objective is to evaluate the effects of action-observation training on tongue strength in brain-damaged patients.
- Trial name
- NCT04615598
- Testing
- Action observation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Universidad Autonoma de Madrid